TG Therapeutics, Inc.

NASDAQ:TGTX

Biotechnology

Healthcare
$66.12 +2.00%

+$1.03 today

Market cap
$9.99B
Beta
1.68
P/E (TTM)
16.4
EPS (TTM)
$3.20
52W Low $25.28High $53.98

Volume 1.87M

Average 2.15M

TGTX Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

TG Therapeutics, Inc.NASDAQ: TGTX

Other Income / Expenses · Q3 FY2026 · quarter ended Sep 2026

Other income / expenses remains negative

Q3 FY2026 other income / expenses was -$12.04M, compared with -$3.46M a year earlier. Trailing-twelve-month other income / expenses was -$43.31M.

Context

  • Other income / expenses amounted to 2.6% of revenue in FY2025, down 2.4 pp from a year earlier.
  • Other income / expenses grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly other income / expenses holds near -$12.04M or moves back toward the trailing-twelve-month quarterly average of -$10.83M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$12.04M-5.2% QoQ
Last fiscal yearDec 2025
-$15.93M+2.5% YoY
LTMSep 2026
-$43.31M-188.2% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-248.3%——
1 year+2.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
(15.93M) USD
Year-over-year change
+2.5%

Other Income / Expenses vs competitors

How TGTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -188.2% is the lowest of 7, against a peer median of +64.4%.
  • Other income / expenses amounts to 4.8% of revenue for TGTX, versus a peer median of 52.6%.
TGTX Competitors
Other Income / Expenses for TGTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XNCRXencor, Inc.LTM Jun 2026$55.23M USD+206.4%+46.5%52.6%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$25.39M USD-19.9%+114.2%22670.5%
ADAGAdagene Inc.LTM Jun 2024$4.52M USD—-7.1%554.5%
IPHAInnate Pharma S.A.FY2025€4.25M EUR+101.9%—152.4%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$3.76M USD+136.9%——
MGNXMacroGenics, Inc.LTM Mar 2026-$7.37M USD-116.5%—4.7%
ADCTADC Therapeutics S.A.LTM Mar 2026-$17.66M USD+27.0%—22.3%
TGTXTG Therapeutics, Inc.LTM Sep 2026-$43.31M USD-188.2%—4.8%
GMABGenmab A/SLTM Jun 2026-$427.99M USD——10.4%
Peer median (excluding TGTX) —+64.4%+46.5%52.6%

Competitors are the stored peer set for TGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.69M2.79M233.66M329M616.29M
Cost of Revenue790K265K14.13M38.49M100.71M
Gross Profit5.9M2.52M219.53M290.52M515.57M
Gross Margin88.2%90.5%94.0%88.3%83.7%
Research & Development222.58M125.35M76.19M94.29M160.22M
Selling, General & Admin128.09M95.48M122.71M154.3M232.03M
Operating Expenses350.67M220.84M198.9M248.59M392.25M
Depreciation & Amortization494K515K423K280K244K
EBITDA(341.97M)(213.11M)26.1M49.9M134.36M
EBITDA Margin-5112.4%-7651.9%11.2%15.2%21.8%
Operating Income(344.77M)(218.32M)20.63M41.93M123.32M
Operating Margin-5154.3%-7839.0%8.8%12.7%20.0%
Interest Income00000
Interest Expense5.64M10.19M12.62M24.03M26.73M
Other Income / Expenses(3.33M)(5.5M)(7.57M)(16.34M)(15.93M)
Income Before Tax(348.1M)(223.81M)13.06M25.59M107.39M
Pre-Tax Margin-5204.1%-8036.3%5.6%7.8%17.4%
Income Tax Expense00390K2.21M(339.79M)
Net Income(348.1M)(223.81M)12.67M23.38M447.18M
Net Margin-5204.1%-8036.3%5.4%7.1%72.6%
EPS (Basic)(2.63)(1.46)0.090.163.10
EPS (Diluted)(2.63)(1.46)0.090.152.77
Weighted Avg Shares132.22M135.41M141.96M145.32M144.32M
Weighted Avg Shares (Diluted)132.22M135.41M148.51M160.34M161.41M

TG Therapeutics, Inc.

NASDAQ:TGTX

Intrinsic Alpha fair value

Locked

Current Price

$66.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.